Meeting
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
Authors
Tony S. K. Mok
Chinese University of Hong Kong, Hong Kong, China
Tony S. K. Mok , Diego Luigi Cortinovis , Margarita Majem , Melissa Lynne Johnson , Feby Ingriani Mardjuadi , Xuan Zhao , Sagar Vidya Siripurapu , Zhiqiang Jiang , Juergen Wolf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04139317
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9118)
DOI
10.1200/JCO.2022.40.16_suppl.9118
Abstract #
9118
Poster Bd #
104
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.
First Author: Yunpeng Yang
Poster
2018 ASCO Annual Meeting
Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
First Author: James Lorens
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2021 ASCO Annual Meeting
Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.
First Author: Mingfang Zhao